Publications by authors named "M Brunetto"
Article Synopsis
- - Primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) are chronic liver diseases that damage bile ducts and lead to liver fibrosis and cirrhosis, but no specific biomarkers exist to differentiate them.
- - This study analyzed saliva samples from 6 PBC patients using advanced mass spectrometry, comparing the results with samples from PSC patients, and identified 40 proteins that were significantly deregulated in PSC.
- - The research revealed that some of these proteins are involved in immune responses and cytoskeleton remodeling, suggesting that saliva could be a valuable source for discovering biomarkers to differentiate between PSC and PBC.
Background&aims: Non-invasive tests (NITs) for ruling-out clinical significant portal hypertension (CSPH) and high-risk varices (HRV) in patients with primary biliary cholangitis(PBC) and compensated advanced chronic liver disease (cACLD) are lacking. We evaluated NITs in these patients and the influence of cholestasis on their performance.
Methods: Consecutive patients from the "Italian PBC registry" and two UK large-volume PBC referral centres with upper endoscopy within 6 months from biochemical evaluation and transient elastography were included.
Article Synopsis
- * A study involving nearly 2,000 non-resectable HCC patients showed that LMWA had comparable safety and overall survival rates to PRFA and significantly better survival rates than TACE after 1, 3, and 5 years.
- * The results suggest that LMWA is a viable treatment option for early HCC, outperforming TACE while demonstrating similar efficacy to PRFA, which supports its potential inclusion in standardized treatment
Article Synopsis
- The study assessed the safety and tolerability of bulevirtide (BLV), a new treatment for chronic hepatitis delta (CHD), by analyzing data from three clinical trials involving 269 patients.
- The findings indicated that certain adverse events, such as increased bile acid levels and injection-site reactions, were more common with BLV compared to a control group, but serious side effects were minimal and did not lead to treatment discontinuation.
- Overall, BLV was deemed safe and well tolerated over 48 weeks of therapy in patients with CHD, showing promise as an effective treatment option.
Development and Validation of a PIVKA-II-Based Model for HCC Risk Stratification in Patients With HCV-Related Cirrhosis Successfully Treated With DAA.
Gian Paolo Caviglia Piero Fariselli Roberta D'Ambrosio Piero Colombatto Elisabetta Degasperi Maurizia Rossana Brunetto
Aliment Pharmacol Ther
November 2024
Article Synopsis
- * Researchers analyzed data from 1,220 patients with HCV-related cirrhosis, creating a risk model using factors like PIVKA-II levels, age, sex, and liver function markers.
- * The model demonstrated good accuracy in distinguishing HCC risk, with low, medium, and high-risk groups showing cumulative incidence rates of 2.7%, 4.0%, and 14.3%